Center for Inquiry Testifies at FDA Hearing on Regulation of Homeopathy

From the Center for Inquiry’s Office of Public Policy:

The Center for Inquiry (CFI) was invited and today delivered oral testimony at the Food and Drug Administration’s first review of its policies regarding the regulation of homeopathic products in more than 25 years.

Michael De Dora, director of CFI’s Office of Public Policy, delivered CFI’s testimony during on the first of a two-day public hearing at the FDA’s White Oak Campus in Silver Spring, MD. His testimony, however, was presented not only behalf of CFI, “but also on behalf of dozens of doctors and scientists associated with CFI and its affiliate program, the Committee for Skeptical Inquiry, with whom we work on these matters.”

In his testimony, De Dora briefly reviewed the scientific evidence on homeopathy, illustrated the harm caused by homeopathy, and proposed actions the FDA should take to hold homeopathic products to the same standards as non-homeopathic drugs in order to fulfill its mandate to protect the American public.

You can read more, including the full testimony, here.